Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Critical evaluation of rituximab rescue in 27 patients with different types of kidney disease.

Ganzemueller J, Hartmann B, Keller F, Stracke S.

Minerva Urol Nefrol. 2011 Dec;63(4):263-72.

PMID:
21996981
3.

[Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].

Chen DB, Wang Y, Song QJ, Shen DH.

Zhonghua Bing Li Xue Za Zhi. 2012 Sep;41(9):607-12. doi: 10.3760/cma.j.issn.0529-5807.2012.09.008. Chinese.

PMID:
23157829
4.

Rituximab is not a "magic drug" in post-transplant recurrence of nephrotic syndrome.

Grenda R, Jarmużek W, Rubik J, Piątosa B, Prokurat S.

Eur J Pediatr. 2016 Sep;175(9):1133-1137. doi: 10.1007/s00431-016-2747-1. Epub 2016 Jun 30.

5.

Combined use of rituximab and plasmapheresis pre-transplant increases post-transplant infections in renal transplant recipients with basiliximab induction therapy.

Chung BH, Yun JT, Ha SE, Kim JI, Moon IS, Choi BS, Park CW, Kim YS, Yang CW.

Transpl Infect Dis. 2013 Dec;15(6):559-68. doi: 10.1111/tid.12135. Epub 2013 Sep 9.

PMID:
24011062
6.

Clinical outcomes of ABO-incompatible kidney transplant with rituximab and double-filtration plasmapheresis.

Han S, Hwang E, Park S, Park U, Kim H, Cho W.

Exp Clin Transplant. 2014 Oct;12(5):401-4.

7.

Post-transplant lymphoproliferative disorder--case reports of three children with kidney transplant.

Spasojević-Dimitrijeva B, Peco-Antić A, Paripović D, Kruscić D, Krstić Z, Cupić M, Cvetković M, Milosevski-Lomić G, Kostić M.

Srp Arh Celok Lek. 2014 Jan-Feb;142(1-2):83-8.

8.

Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil.

Kabei K, Uchida J, Iwai T, Yamasaki T, Kuwabara N, Naganuma T, Kumada N, Nakatani T.

Transpl Immunol. 2014 Aug;31(2):92-7. doi: 10.1016/j.trim.2014.06.001. Epub 2014 Jun 13.

PMID:
24932811
9.

Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.

Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, Camara Rde L, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.

Clin Infect Dis. 2013 Sep;57(6):794-802. doi: 10.1093/cid/cit391. Epub 2013 Jun 13.

PMID:
23771985
10.

Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.

Miyagi S, Sekiguchi S, Kawagishi N, Akamatsu Y, Satoh K, Takeda I, Fukushima D, Kobayashi Y, Tokodai K, Fujimori K, Satomi S.

Transplant Proc. 2011 Nov;43(9):3299-301. doi: 10.1016/j.transproceed.2011.10.002.

PMID:
22099782
11.

Long-term effect of rituximab in maintaining remission of recurrent and plasmapheresis-dependent nephrotic syndrome post-renal transplantation - case report.

Grenda R, Jarmużek W, Piątosa B, Rubik J.

Pediatr Transplant. 2011 Sep;15(6):E121-5. doi: 10.1111/j.1399-3046.2010.01303.x. Epub 2010 Mar 16.

PMID:
20331516
12.

Fatal late-onset Pneumocystis pneumonia after rituximab: administration for posttransplantation recurrence of focal segmental glomerulosclerosis--case report.

Dęborska-Materkowska D, Kozińska-Przybył O, Mikaszewska-Sokolewicz M, Durlik M.

Transplant Proc. 2014 Oct;46(8):2908-11. doi: 10.1016/j.transproceed.2014.09.010.

PMID:
25380948
13.

Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation.

Tsagalis G, Psimenou E, Nakopoulou L, Laggouranis A.

Artif Organs. 2011 Apr;35(4):420-5. doi: 10.1111/j.1525-1594.2010.01068.x.

PMID:
20637013
14.

Rituximab in highly sensitized kidney transplant recipients.

Munoz AS, Rioveros AA, Cabanayan-Casasola CB, Danguilan RA, Ona ET.

Transplant Proc. 2008 Sep;40(7):2218-21. doi: 10.1016/j.transproceed.2008.07.046.

PMID:
18790197
15.

ABO-incompatible kidney transplantation in elderly patients over 60 years of age.

Uchida J, Iwai T, Machida Y, Kuwabara N, Kabei K, Murao M, Otoshi T, Naganuma T, Kumada N, Nakatani T.

Int Urol Nephrol. 2012 Oct;44(5):1563-70. doi: 10.1007/s11255-012-0231-z. Epub 2012 Jul 25.

16.

Antibody-mediated rejection and treatment in pediatric patients: one center's experience.

Gulleroglu K, Baskin E, Bayrakci US, Turan M, Ozdemir BH, Moray G, Karakayali H, Haberal M.

Exp Clin Transplant. 2013 Oct;11(5):404-7.

17.

Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.

Trappe R, Riess H, Babel N, Hummel M, Lehmkuhl H, Jonas S, Anagnostopoulos I, Papp-Vary M, Reinke P, Hetzer R, Dörken B, Oertel S.

Transplantation. 2007 Apr 15;83(7):912-8.

PMID:
17460562
18.

Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome.

Ito S, Kamei K, Ogura M, Udagawa T, Fujinaga S, Saito M, Sako M, Iijima K.

Pediatr Nephrol. 2013 Feb;28(2):257-64. doi: 10.1007/s00467-012-2319-1. Epub 2012 Oct 10.

PMID:
23052656
19.

Indications for use and safety of rituximab in childhood renal diseases.

Tullus K, Marks SD.

Pediatr Nephrol. 2013 Jul;28(7):1001-9. doi: 10.1007/s00467-012-2260-3. Epub 2012 Sep 21. Review.

PMID:
22992983
20.

Efficacy and safety of rituximab treatment in children with primary glomerulonephritis.

Zachwieja J, Silska M, Ostalska-Nowicka D, Soltysiak J, Lipkowska K, Blumczynski A, Musielak A.

J Nephrol. 2012 Nov-Dec;25(6):1060-6. doi: 10.5301/jn.5000096.

PMID:
22322817

Supplemental Content

Support Center